Literature DB >> 19943854

Tau oligomers and aggregation in Alzheimer's disease.

Marco A Meraz-Ríos1, Karla I Lira-De León, Victoria Campos-Peña, Martha A De Anda-Hernández, Raúl Mena-López.   

Abstract

We are analyzing the physiological function of Tau protein and its abnormal pathological behavior when this protein is self-assemble into pathological filaments. These aggregates of Tau protein are the main components in many diseases such as Alzheimer's disease (AD). Recent studies suggest that Tau acquires complex oligomeric conformations which may be toxic. In this review, we emphasized the possible phenomena implicated in the formation of these oligomers. Studies with chemical inductors indicates that the microtubule-binding domain is the most important region involved in Tau aggregation and showed the requirement of a pre-arrange Tau in abnormal conformation to promote self-assembly. Transgenic animal models and AD neuropathology studies showed that post-translational modifications are also implicated in Tau aggregation and neural cell death during AD development. Therefore, we analyzed some events that could be present during Tau aggregation. Finally, we included a brief discussion of the possible relation between glucose metabolism dysfunction in AD, and data of Tau aggregation by using aggregation inhibitors. In conclusion, the process Tau aggregation deserves further investigations to design possible therapeutic targets to inhibit the toxicity of these aggregates and it is possible that could be extended to other diseases with similar etiology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19943854     DOI: 10.1111/j.1471-4159.2009.06511.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  49 in total

1.  Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Authors:  Sophie Sokolow; Kristen M Henkins; Tina Bilousova; Bianca Gonzalez; Harry V Vinters; Carol A Miller; Lindsey Cornwell; Wayne W Poon; Karen H Gylys
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 3.  Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology.

Authors:  Daniel J Glass; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2011-12-03       Impact factor: 21.566

4.  Rho-kinase ROCK inhibitors reduce oligomeric tau protein.

Authors:  Tadanori Hamano; Norimichi Shirafuji; Shu-Hui Yen; Hirotaka Yoshida; Nicholas M Kanaan; Kouji Hayashi; Masamichi Ikawa; Osamu Yamamura; Youshi Fujita; Masaru Kuriyama; Yasunari Nakamoto
Journal:  Neurobiol Aging       Date:  2019-12-16       Impact factor: 4.673

5.  Isolation and characterization of antibody fragment selective for human Alzheimer's disease brain-derived tau variants.

Authors:  Lalitha Venkataraman; Ping He; Philip Schulz; Michael R Sierks
Journal:  Neurobiol Aging       Date:  2020-04-24       Impact factor: 4.673

6.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

7.  A DEHP plasticizer alters synaptic proteins via peroxidation.

Authors:  Shaohui Wang; Pengyan Zhang; Ruifang Liu; Yuan Li; Chao Liu; Xiaomei Liao
Journal:  Toxicol Res (Camb)       Date:  2016-11-02       Impact factor: 3.524

Review 8.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 9.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe.

Authors:  Hye-Yeong Kim; Urmi Sengupta; Pin Shao; Marcos J Guerrero-Muñoz; Rakez Kayed; Mingfeng Bai
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.